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Abstract
The Australian Group on Antimicrobial Resistance 
performs regular period-prevalence studies to 
monitor changes in antimicrobial resistance 
in selected enteric Gram-negative pathogens. 
The 2012 survey focussed on community-onset 
infections, examining isolates from urinary tract 
infections from patients presenting to outpatient 
clinics, emergency departments or to community 
practitioners. In 2012, 2,025 Escherichia coli, 
538 Klebsiella species and 239 Enterobacter spe-
cies were tested using a commercial automated 
method (Vitek 2, BioMérieux) and results were 
analysed using Clinical and Laboratory Standards 
Institute breakpoints from January 2012. Of the 
key resistances, non-susceptibility to the third-
generation cephalosporin, ceftriaxone, was found 
in 4.2% of E. coli and 4.6%–6.9% of Klebsiella 
spp. Non-susceptibility rates to ciprofloxacin 
were 6.9% for E. coli, 0.0%–3.5% for Klebsiella 
spp. and 0.8%–1.9% in Enterobacter spp, and 
resistance rates to piperacillin-tazobactam were 
1.7%, 0.7%–9.2%, and 8.8%–11.4% for the same 
3 groups respectively. Only 1 Enterobacter cloacae 
was shown to harbour a carbapenemase (IMP-4). 
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Introduction
Emerging resistance in common pathogenic 
members of the family Enterobacteriaceae is a 
world-wide phenomenon, and presents therapeutic 
problems for practitioners in both the community 
and in hospital practice. The Australian Group on 
Antimicrobial Resistance commenced surveillance 
of the key Gram-negative pathogens, Escherichia 
coli and Klebsiella species in 1992. Surveys have 
been conducted biennially until 2008 when annual 
surveys commenced alternating between commu-
nity– and hospital-onset infections (http://www.
agargroup.org/surveys). In 2004, another genus of 
Gram-negative pathogens in which resistance can 
be of clinical importance, Enterobacter species, was 
added. E. coli is the most common cause of commu-
nity-onset urinary tract infection, while Klebsiella 
species are less common but are known to harbour 
important resistances. Enterobacter species are less 
common in the community, but of high importance 
due to intrinsic resistance to first-line antimicrobials 
in the community. Taken together, the 3 groups of 
species surveyed are considered to be valuable senti-
nels for multi-resistance and emerging resistance in 
enteric Gram-negative bacilli.
Resistances of particular interest include resist-
ance to ß-lactams due to ß-lactamases, especially 
extended-spectrum ß-lactamases, which inac-
tivate the third-generation cephalosporins that 
are normally considered reserve antimicrobials. 
Other resistances of interest include resistance to 
antibiotics commonly used in the community such 
as trimethoprim; resistance to agents important for 
serious infections, such as gentamicin; and resist-
ance to reserve agents such as ciprofloxacin and 
meropenem.
The objectives of the 2012 surveillance program 
were to:
1. determine proportions of resistance to the main 
therapeutic agents in Escherichia coli, Klebsiella 
species and Enterobacter species in a subset of 
Australian diagnostic laboratories;
2. examine the extent of co-resistance and multi-
resistance in these species; and
3. detect emerging resistance to newer last-line 
agents such as carbapenems. Isolates from the 
urinary tract were selected for this program.
Methods
Source of isolates
Isolates were collected from non-hospitalised 
patients with urinary tract infections, including 
those presenting to emergency departments, out-
patient departments or to community practition-
ers. Each institution collected up to 70 E. coli, 
20 Klebsiella spp. and 10 Enterobacter spp. isolates. 
Urinary tract isolates were selected because of their 
high frequency and high rates of exposure to anti-
microbial agents in the community.
Species identification
Isolates were identified by one of the follow-
ing methods: Vitek®; Phoenix™ Automated 
Microbiology System, Microbact; ATB®; or agar 
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replication. In addition, some E. coli isolates were 
identified using chromogenic agar plus spot indole 
(DMACA).
Susceptibility testing
Testing was performed by a commercial semi-
automated method, Vitek® 2 (BioMérieux), which 
is calibrated to the ISO reference standard method 
of broth microdilution. Commercially available 
Vitek® AST-N246 cards were utilised by all par-
ticipants throughout the survey period. The most 
recent Clinical and Laboratory Standards Institute 
breakpoints from 20131 were employed in the 
analysis. E. coli ATCC 25922 and E. coli ATCC 
35218 were the quality control strains for this sur-
vey. For analysis of cefazolin, breakpoints of ≤4 for 
susceptible and ≥8 for resistant were applied due 
to the minimum inhibitory concentration (MIC) 
range available on the Vitek card, recognising that 
the January 2013 breakpoint is actually susceptible 
≤2 mg/L. Non-susceptibility, (which includes 
both intermediately resistant and resistant strains), 
has been included for some agents because these 
figures provide information about important 
emerging acquired resistances.
Molecular confirmation of resistances
E. coli and Klebsiella isolates with ceftazidime 
or ceftriaxone MIC >1 mg/L, or cefoxitin MIC 
>8 mg/L; Enterobacter spp. with cefepime MIC 
>1 mg/L; and all isolates with meropenem MIC 
>0.25 mg/L were referred to a central laboratory 
for molecular confirmation of resistance.
All isolates were screened for the presence of the 
blaTEM, and blaSHV genes using a real-time polymer-
ase chain reaction (PCR) platform (LC-480) and 
published primers.2,3 A multiplex real-time TaqMan 
PCR was used to detect CTX-M-type genes.4 
Strains were probed for plasmid-borne AmpC 
enzymes using the method described by Pérez-
Pérez and Hanson,5. and subjected to molecular 
tests for MBL (blaVIM, blaIMP, and blaNDM), blaKPC, 
and blaOXA-48-like genes using real-time PCR.
6,7
Results
In 2012, 2,802 isolates were examined, comprising 
2,025 E. coli, 538 Klebsiella spp. and 239 Enterobacter 
spp. (Table 1). Major resistances and non-suscep-
tibilities are listed in Table 2. Multi-resistance was 
detected in 7.6% of E. coli isolates, 5.1% of Klebsiella 
spp. and 5.4% of Enterobacter spp. (Table 3). A 
more detailed breakdown of resistances and non-
susceptibilities by state and territory is provided 
in the online report from the group (http://www.
agargroup.org/surveys). By way of summary, there 
were no substantial differences across the states and 
territories in resistance patterns in contrast to what 
is seen with resistance patterns in Staphylococcus 
aureus and Enterococcus spp.
Escherichia coli
Moderately high levels of resistance to ampicillin 
(and therefore amoxycillin) were observed (44.3%), 
with lower rates for amoxycillin-clavulanate 
(11.3% intermediate, 5.3% resistant) (Table 2). 
Non-susceptibility to third-generation cephalo-
sporins was low but appears to be increasing slowly 
compared with the 2010 survey (ceftriaxone 4.2%, 
ceftazidime 2.2%). In line with international trends 
amongst community strains of E. coli, most of 
the strains with extended-spectrum ß-lactamase 
(ESBL) genes harboured genes of the CTX-M type 
(75%, 68/91). Moderate levels of resistance were 
detected to cefazolin (14.3%) and trimethoprim 
(22.7%). Ciprofloxacin non-susceptibility was found 
in 6.9% of E. coli isolates. Ciprofloxacin resistance 
was found in 51.8% and gentamicin resistance 
was found in 30.1% of ESBL-producing strains. 
Resistance to ticarcillin-clavulanate, piperacillin-
tazobactam, cefepime, and gentamicin were below 
5%. No isolates had elevated meropenem MICs.
Klebsiella species
These isolates showed slightly higher levels of 
resistance to cefazolin, ceftriaxone and piperacil-
lin-tazobactam compared with E. coli, but lower 
rates of resistance to amoxycillin-clavulanate, 
ticarcillin-clavulanate, ciprofloxacin, gentamicin, 
and trimethoprim (Table 2). ESBLs were present 
in 17 of 21 presumptively ESBL-positive isolates 
of K. pneumoniae, 14 of which proved to be of the 
CTX-M type. No Klebsiella species had elevated 
meropenem MICs.
Table 1: Species tested
Group Species Total
E. coli E. coli 2,025
Klebsiella K. pneumoniae 434
K. oxytoca 101
K. pneumoniae subsp ozaenae 3
Total 538




Enterobacter not speciated 1
Total 239
E56 CDI Vol 38 No 1 2014
Annual reports Community-onset Gram-negative Surveillance Program, 2012












Ampicillin I 1.9 † † † †
Ampicillin R 44.3 † † † †
Amoxycillinclavulanate I 11.3 2.8 1.0 † †
Amoxycillinclavulanate R 5.3 2.1 9.9 † †
Ticarcillin-clavulanate R 5.7 1.8 12.5 16.8 19.8
Piperacillintazobactam R 1.7 0.7 9.2 8.8 11.4
Cefazolin R 14.3 6.9 75.8 † †
Cefoxitin R 1.5 1.4 0.0 † †
Ceftriaxone NS 4.2 4.6 6.9 27.3 21.5
Ceftazidime NS 2.2 3.0 0.0 19.5 18.7
Cefepime NS 0.7 0.5 0.0 0.8 0.0
Meropenem NS 0.0 0.0 0.0 1.6 0.0
Ciprofloxacin NS 6.9 3.5 0.0 0.8 1.9
Norfloxacin NS 6.8 2.3 0.0 0.0 1.9
Gentamicin NS 4.5 3.0 0.0 5.5 0.0
Trimethoprim R 22.7 9.9 3.0 17.2 1.9
Nitrofurantoin NS 5.4 † † † †
* R = resistant, I = intermediate, NS = non-susceptible (intermediate + resistant).
†	 Considered	largely	intrinsically	resistant	due	to	natural	β-lactamases.
Table 3: Multiple acquired resistances, by species
Number of acquired resistances
Non-multi-resistant Multi-resistant
Species Total 0 1 2 3
Cumulative 
% 4 5 6 7 8 9 10 11
Cumulative 
%
E. coli 1,871 940 368 304 117 62 33 23 16 4 3 1
% 50.2 19.7 16.2 6.3 92.4 3.3 1.8 1.2 0.9 0.2 0.2 0.1 7.6
Klebsiella spp.* 508 303 150 21 8 12 4 5 3 2
% 59.6 29.5 4.1 1.6 94.9 2.4 0.8 1.0 0.6 0.4 5.1
Enterobacter spp.† 224 122 51 19 20 7 4 1
% 54.5 22.8 85.0 8.9 94.6 3.1 1.8 0.4 5.4
* Antibiotics included: amoxycillin-clavulanate, piperacillin-tazobactam, cefazolin, cefoxitin, ceftriaxone, ceftazidime, cefepime, 
gentamicin,	amikacin,	ciprofloxacin,	nitrofurantoin,	trimethoprim,	meropenem.
	 Antibiotics	excluded:	ampicillin	(intrinsic	resistance),	ticarcillin-clavulanate,	tobramycin,	norfloxacin,	nalidixic	acid,	sulfamethox-
azole-trimethoprim (high correlation with antibiotics in the included list).
†	 Antibiotics	included:	piperacillin-tazobactam,	ceftriaxone,	ceftazidime,	cefepime,	gentamicin,	amikacin,	ciprofloxacin,	nitrofuran-
toin, trimethoprim, meropenem 
 
Antibiotics excluded: ampicillin, amoxycillin-clavulanate, cefazolin, and cefoxitin, (all four due to intrinsic resistance); also 
excluded	were	ticarcillin-clavulanate,	tobramycin,	norfloxacin,	nalidixic	acid,	sulfamethoxazole-trimethoprim	(high	correlation	
with antibiotics in the included list).
Enterobacter species
Acquired resistance was common to ticarcillin-
clavulanate (17.8%), piperacillin-tazobactam 
(9.8%), ceftriaxone (24.3%), ceftazidime (18.8%) 
and trimethoprim (10.0%) (Table 2). Rates of 
resistance to cefepime, ciprofloxacin, and gen-
tamicin were all less than 5%. Three of 4 strains 
tested for ESBL based on a suspicious phenotype, 
harboured ESBL-encoding genes. Two strains had 
elevated meropenem MICs (≥ 0.5 mg/L) one of 
which harboured blaIMP-4.
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Discussion
The Australian Group on Antimicrobial Resistance 
has been tracking resistance in sentinel enteric 
Gram-negative bacteria since 1992. Until 2008, 
surveillance was segregated into hospital– versus 
community-onset infections. The first year of 
community-onset only surveillance was 2008.8 
Comparing results from that year with 2012, there 
has been a noticeable increase in resistance rates to 
some important and reserve antibiotics. For exam-
ple, rates of resistance in E. coli for ceftriaxone rose 
from 2.1% to 4.2% and for non-susceptibility to 
ciprofloxacin rose from 4.2% to 6.9%. Intermediate 
percentages were observed in 2010, confirming the 
definite upward trend.
Overall though, there are worrying trends in 
the emergence of CTX-M-producing E. coli 
and Klebsiella species and gentamicin– and 
ciprofloxacin-resistant E. coli now presenting in 
or from the community. Other resistance patterns 
appear stable. Carbapenem resistance attributable 
to acquired carbapenemases are still rare in com-
munity onset infections in Australia. Compared 
with many other countries in our region, resistance 
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